Drug interaction between clopidogrel and proton pump inhibitors

Saira Chand Khalique, Angela Cheng-Lai

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Dual antiplatelet therapy with clopidogrel and aspirin has been shown to reduce recurrent cardiac events in patients with acute coronary syndromes or those who have undergone coronary artery stent placement. Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to an active metabolite by the cytochrome P450 enzyme system. Due to the increased risk of bleeding in patients on dual antiplatelet therapy, concomitant gastrointestinal ulcer prophylaxis with a proton pump inhibitor (PPI) is frequently prescribed. Data from recent studies show that PPIs, which are extensively metabolized by the cytochrome system, may decrease the antiplatelet activity of clopidogrel. This article reviews the metabolism of various PPIs and existing data regarding the drug-drug interaction between PPIs and clopidogrel.

Original languageEnglish (US)
Pages (from-to)198-200
Number of pages3
JournalCardiology in Review
Volume17
Issue number4
DOIs
StatePublished - Jul 2009

Fingerprint

clopidogrel
Proton Pump Inhibitors
Drug Interactions
Cytochrome P-450 Enzyme System
Prodrugs
Cytochromes
Acute Coronary Syndrome
Aspirin
Ulcer
Stents
Coronary Vessels
Hemorrhage
Therapeutics
Pharmaceutical Preparations

Keywords

  • Adverse outcomes
  • Clopidogrel
  • Interaction
  • Plavix
  • PPI
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Drug interaction between clopidogrel and proton pump inhibitors. / Khalique, Saira Chand; Cheng-Lai, Angela.

In: Cardiology in Review, Vol. 17, No. 4, 07.2009, p. 198-200.

Research output: Contribution to journalArticle

@article{30eacd2f17c44dc6ae926158d406dbf2,
title = "Drug interaction between clopidogrel and proton pump inhibitors",
abstract = "Dual antiplatelet therapy with clopidogrel and aspirin has been shown to reduce recurrent cardiac events in patients with acute coronary syndromes or those who have undergone coronary artery stent placement. Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to an active metabolite by the cytochrome P450 enzyme system. Due to the increased risk of bleeding in patients on dual antiplatelet therapy, concomitant gastrointestinal ulcer prophylaxis with a proton pump inhibitor (PPI) is frequently prescribed. Data from recent studies show that PPIs, which are extensively metabolized by the cytochrome system, may decrease the antiplatelet activity of clopidogrel. This article reviews the metabolism of various PPIs and existing data regarding the drug-drug interaction between PPIs and clopidogrel.",
keywords = "Adverse outcomes, Clopidogrel, Interaction, Plavix, PPI, Proton pump inhibitors",
author = "Khalique, {Saira Chand} and Angela Cheng-Lai",
year = "2009",
month = "7",
doi = "10.1097/CRD.0b013e3181a857ba",
language = "English (US)",
volume = "17",
pages = "198--200",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Drug interaction between clopidogrel and proton pump inhibitors

AU - Khalique, Saira Chand

AU - Cheng-Lai, Angela

PY - 2009/7

Y1 - 2009/7

N2 - Dual antiplatelet therapy with clopidogrel and aspirin has been shown to reduce recurrent cardiac events in patients with acute coronary syndromes or those who have undergone coronary artery stent placement. Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to an active metabolite by the cytochrome P450 enzyme system. Due to the increased risk of bleeding in patients on dual antiplatelet therapy, concomitant gastrointestinal ulcer prophylaxis with a proton pump inhibitor (PPI) is frequently prescribed. Data from recent studies show that PPIs, which are extensively metabolized by the cytochrome system, may decrease the antiplatelet activity of clopidogrel. This article reviews the metabolism of various PPIs and existing data regarding the drug-drug interaction between PPIs and clopidogrel.

AB - Dual antiplatelet therapy with clopidogrel and aspirin has been shown to reduce recurrent cardiac events in patients with acute coronary syndromes or those who have undergone coronary artery stent placement. Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to an active metabolite by the cytochrome P450 enzyme system. Due to the increased risk of bleeding in patients on dual antiplatelet therapy, concomitant gastrointestinal ulcer prophylaxis with a proton pump inhibitor (PPI) is frequently prescribed. Data from recent studies show that PPIs, which are extensively metabolized by the cytochrome system, may decrease the antiplatelet activity of clopidogrel. This article reviews the metabolism of various PPIs and existing data regarding the drug-drug interaction between PPIs and clopidogrel.

KW - Adverse outcomes

KW - Clopidogrel

KW - Interaction

KW - Plavix

KW - PPI

KW - Proton pump inhibitors

UR - http://www.scopus.com/inward/record.url?scp=68049115736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049115736&partnerID=8YFLogxK

U2 - 10.1097/CRD.0b013e3181a857ba

DO - 10.1097/CRD.0b013e3181a857ba

M3 - Article

VL - 17

SP - 198

EP - 200

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 4

ER -